These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

91 related articles for article (PubMed ID: 6152344)

  • 1. Cholecystokinin-octapeptide in chronic schizophrenia: a double-blind placebo-controlled study.
    Nair NP; Bloom DM; Debonnel G; Schwartz G; Mosticyan S
    Prog Neuropsychopharmacol Biol Psychiatry; 1984; 8(4-6):711-4. PubMed ID: 6152344
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cholecystokinin appears to have antipsychotic properties.
    Nair NP; Bloom DM; Nestoros JN
    Prog Neuropsychopharmacol Biol Psychiatry; 1982; 6(4-6):509-12. PubMed ID: 6891817
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Double blind controlled trials of cholecystokinin octapeptide in neuroleptic-refractory schizophrenia.
    Peselow E; Angrist B; Sudilovsky A; Corwin J; Siekierski J; Trent F; Rotrosen J
    Psychopharmacology (Berl); 1987; 91(1):80-4. PubMed ID: 2881320
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The effects of ceruletide in schizophrenia.
    Hommer DW; Pickar D; Roy A; Ninan P; Boronow J; Paul SM
    Arch Gen Psychiatry; 1984 Jun; 41(6):617-9. PubMed ID: 6329121
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Naltrexone augmentation of neuroleptics in schizophrenia.
    Sernyak MJ; Glazer WM; Heninger GR; Charney DS; Woods SW; Petrakis IL; Krystal JH; Price LH
    J Clin Psychopharmacol; 1998 Jun; 18(3):248-51. PubMed ID: 9617985
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Quetiapine in patients with schizophrenia. A high- and low-dose double-blind comparison with placebo. Seroquel Study Group.
    Small JG; Hirsch SR; Arvanitis LA; Miller BG; Link CG
    Arch Gen Psychiatry; 1997 Jun; 54(6):549-57. PubMed ID: 9193196
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A double-blind, placebo-controlled trial of extract of Ginkgo biloba added to haloperidol in treatment-resistant patients with schizophrenia.
    Zhang XY; Zhou DF; Zhang PY; Wu GY; Su JM; Cao LY
    J Clin Psychiatry; 2001 Nov; 62(11):878-83. PubMed ID: 11775047
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Control group bias in randomized atypical antipsychotic medication trials for schizophrenia.
    Woods SW; Gueorguieva RV; Baker CB; Makuch RW
    Arch Gen Psychiatry; 2005 Sep; 62(9):961-70. PubMed ID: 16143728
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Amisulpride augmentation in patients with schizophrenia partially responsive or unresponsive to clozapine. A randomized, double-blind, placebo-controlled trial.
    Assion HJ; Reinbold H; Lemanski S; Basilowski M; Juckel G
    Pharmacopsychiatry; 2008 Jan; 41(1):24-8. PubMed ID: 18203048
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Lithium addition to neuroleptic treatment in chronic schizophrenia: a randomized, double-blind, placebo-controlled, cross-over study.
    Terao T; Oga T; Nozaki S; Ohta A; Ohtsubo Y; Yamamoto S; Zamami M; Okada M
    Acta Psychiatr Scand; 1995 Sep; 92(3):220-4. PubMed ID: 7484202
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Vasopressin in anergic schizophrenia. A cross-over study with lysine-8-vasopressin and placebo.
    Korsgaard S; Casey DE; Damgaard Pedersen NE; Jørgensen A; Gerlach J
    Psychopharmacology (Berl); 1981; 74(4):379-82. PubMed ID: 6794086
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Antipsychotic efficacy of the antidepressant trimipramine: a randomized, double-blind comparison with the phenothiazine perazine.
    Bender S; Olbrich HM; Fischer W; Hornstein C; Schoene W; Falkai P; Haarmann C; Berger M; Gastpar M;
    Pharmacopsychiatry; 2003; 36(2):61-9. PubMed ID: 12734763
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Aripiprazole augmentation in clozapine-treated patients with refractory schizophrenia: an 8-week, randomized, double-blind, placebo-controlled trial.
    Chang JS; Ahn YM; Park HJ; Lee KY; Kim SH; Kang UG; Kim YS
    J Clin Psychiatry; 2008 May; 69(5):720-31. PubMed ID: 18370574
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Switching from 2 antipsychotics to 1 antipsychotic in schizophrenia: a randomized, double-blind, placebo-controlled study.
    Borlido C; Remington G; Graff-Guerrero A; Arenovich T; Hazra M; Wong A; Daskalakis ZJ; Mamo DC
    J Clin Psychiatry; 2016 Jan; 77(1):e14-20. PubMed ID: 26845273
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Switching to olanzapine after unsuccessful treatment with risperidone during the first episode of schizophrenia: an open-label trial.
    Takahashi H; Kamata M; Yoshida K; Ishigooka J; Higuchi H
    J Clin Psychiatry; 2006 Oct; 67(10):1577-82. PubMed ID: 17107250
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The effects of a selective D4 dopamine receptor antagonist (L-745,870) in acutely psychotic inpatients with schizophrenia. D4 Dopamine Antagonist Group.
    Kramer MS; Last B; Getson A; Reines SA
    Arch Gen Psychiatry; 1997 Jun; 54(6):567-72. PubMed ID: 9193198
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Quetiapine : A Review of its Use in Schizophrenia.
    Gunasekara NS; Spencer CM
    CNS Drugs; 1998 Apr; 9(4):325-40. PubMed ID: 27521016
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Therapeutic effect of shuxuening combining neuroleptics for the treatment of chronic schizophrenia--a double blind study].
    Luo HC; Shen YC; Meng FQ
    Zhongguo Zhong Xi Yi Jie He Za Zhi; 1997 Mar; 17(3):139-42. PubMed ID: 9863076
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Improvement of negative and positive symptoms in treatment-refractory schizophrenia: a double-blind, randomized, placebo-controlled trial with memantine as add-on therapy to clozapine.
    de Lucena D; Fernandes BS; Berk M; Dodd S; Medeiros DW; Pedrini M; Kunz M; Gomes FA; Giglio LF; Lobato MI; Belmonte-de-Abreu PS; Gama CS
    J Clin Psychiatry; 2009 Oct; 70(10):1416-23. PubMed ID: 19906345
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cholecystokinin peptides, dopamine and schizophrenia--a review.
    Nair NP; Lal S; Bloom DM
    Prog Neuropsychopharmacol Biol Psychiatry; 1985; 9(5-6):515-24. PubMed ID: 2868491
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.